MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest growing drug classes in human healthcare. lt br / gt lt br / gt Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. lt br / gt lt br / gt Over therapeutic antibody programs based on the company s technologies are currently in development, of which are in clinical trials. The company s most advanced proprietary program is MOR , a first in class antibody against GM CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR is part of MorphoSys s collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR and MOR , both for the treatment of cancer. lt br / gt lt br / gt MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
Quote | Morphosys Ag Ord (OTCMKTS:MPSYF)
Last: | $73.27 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $73.27 |
High: | $0 |
Low: | $0 |
Volume: | 200 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Morphosys Ag Ord (OTCMKTS:MPSYF)
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
2024-06-16 08:12:27 ET Summary In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $...
Message Board Posts | Morphosys Ag Ord (OTCMKTS:MPSYF)
Subject | By | Source | When |
---|---|---|---|
Emylers: MPSYF Financials 07/16/2014 03:24:38 MorphoSys AG Period Ending Total Revenue Cost of Reven | Emylers | investorshangout | 07/16/2014 8:24:35 AM |
Stock_Tracker: Latest Morphosys Ag (MPSYF) Headlines Novartis Strengthens in Oncology With Multiple | Stock_Tracker | investorshangout | 03/10/2014 8:40:12 PM |
chartguy89: MPSYF 97.21 Stock Charts $MPSYF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 9:38:56 PM |
chartguy89: MPSYF Stock Charts Last: -0.70 Friday, February 28, 2014 at 2:05:11 AM $MPSYF 1 | chartguy89 | investorshangout | 02/28/2014 7:05:23 AM |
News, Short Squeeze, Breakout and More Instantly...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...